A geometric mean ratio of 1.21 sounds like a dry statistician’s footnote — but for TG Therapeutics, it is the number that determines whether a quarterly at-home injection can displace a clinic infusion for hundreds of thousands of people with relapsing multiple sclerosis. Phase 1 data released Tuesday show that a 400 mg/2 mL subcutaneous formulation of BRIUMVI (ublituximab-xiiy), delivered across more than 225 injections to over 80 patients, achieved mean bioavailability exceeding 60% relative to IV administration — and both dosing regimens modeled for Phase 3 cleared the non-inferiority threshold of 0.80 for the lower bound of the 90% confidence interval with room to spare.
The trial’s design elegance is worth noting. Rather than treating bioavailability as a standalone success criterion, TG used Phase 1 PK data to run modeling and simulation that directly pre-validated the Phase 3 primary endpoint logic. The quarterly arm produced a GMR of 1.21 versus IV BRIUMVI; the every-other-month arm reached 1.58. Both represent higher total drug exposure than IV, not merely equivalent — which gives the non-inferiority argument a wide margin. B-cell depletion tracked consistently with the IV formulation, confirming biological activity isn’t being sacrificed for convenience. On safety, local injection-site reactions appeared in fewer than 5% of patients, systemic injection-related reactions in roughly 21%, all resolved completely, and none were dose-dependent. That tolerability profile matters enormously for a self-administered product, where reactions that spike after the first dose and vanish are far more manageable than persistent or escalating ones.
The competitive context sharpens the strategic logic. The anti-CD20 class in RMS includes ocrelizumab (Ocrevus) and ofatumumab (Kesimpta), and the broader MS therapeutics market is projected near $30.7 billion in 2026, with B-cell depleting agents commanding a dominant share. Kesimpta already occupies the self-injection segment with monthly dosing. Quarterly subcutaneous BRIUMVI, if Phase 3 confirms PK non-inferiority, would offer a substantially lower annual injection burden — four doses versus twelve. That difference in dosing frequency is a real differentiator for patient adherence conversations, not a marginal one.
The fully enrolled Phase 3 trial carries a top-line readout expected at year-end 2026 or early 2027, with a potential approval target of 2028. The single number to watch between now and that readout is whether the lower bound of the 90% CI for the quarterly arm’s GMR holds above 0.80 in actual trial data — the Phase 1 modeling gives a confident lower bound of 1.15, but modeling and trial execution are different animals, and that gap is where approval risk lives.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
